BridgeBio Pharma, Inc. (BBIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$882.0M
Cash & Equivalents
$197.3M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$16,838M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
ACORAMIDIS HYDROCHLORIDE
ATTRUBY 		APPROVED ATTR Amyloidosis With Cardiomyopathy, Heart Failure, Metastatic NSCLC, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Solid Tumor, Solid Tumor, Adult, Transthyretin (TTR) Amyloid Cardiomyopathy, Tumor, Solid

Upcoming Catalysts

DateEventDrug
2026-11-27 Pdufa —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07062848 An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultraso... OTHER Active Not Recruiting 1,500,000

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-07-02 8-K BridgeBio Pharma, Inc. (BBIO) (CIK 0001743881) - EXHIBIT 10.1 EDGAR
2026-05-27 8-K BridgeBio Pharma, Inc. (BBIO) (CIK 0001743881) - EXHIBIT 99.1 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BBIO.

SEC EDGAR Filings

All SEC filings for BridgeBio Pharma, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.